Oral Composition
By combining sugar alcohol, condensed phosphoric acid or its salts, and water in a specific ratio, the viscosity of the composition is controlled, solving the problem of sugar alcohol dripping and achieving good spreadability, adhesion, and plaque dispersion, thus improving the user experience and teeth cleaning effect.
Patent Information
- Application Number
- CN202580029400.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-23
- Filing Date
- 2025-04-22
- Publication Date
- 2026-11-17
AI Technical Summary
Existing oral care compositions contain sugar alcohols that are easily soluble, causing them to drip from the mouth during use. This is especially inconvenient for users with excessive saliva and makes it difficult to effectively remove plaque.
By combining sugar alcohols, condensed phosphates or their salts, and water in specific proportions, the viscosity characteristics of the composition are controlled to ensure good spreadability and adhesion, prevent dripping, and improve plaque dispersibility.
It achieves good spreadability and adhesion in the oral cavity, prevents dripping, improves plaque dispersion and feel, and provides a comfortable brushing experience.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention relates to a composition for oral use. Background Technology
[0002] To date, sugar alcohols such as erythritol or xylitol are known as ingredients that can bring about a variety of effects and are widely used in oral compositions.
[0003] For example, Patent Document 1 discloses an oral composition containing myristoyl glutamic acid or its salt, lauryl glutamic acid or its salt, alkyl sulfate, and water in specified amounts, and attempts to further enhance the biofilm dispersion or bactericidal effect by further containing erythritol. Additionally, Patent Document 2 discloses an oral composition containing N-acyl amino acids or their salts, and pyrophosphate or its salts in specific amounts, and describes how the addition of xylitol or similar substances can improve the user experience.
[0004] (Patent Document 1) Japanese Patent Application Publication No. 2018-39742
[0005] (Patent Document 2) Japanese Patent Application Publication No. 2014-12655 Summary of the Invention
[0006] The present invention provides an oral composition comprising the following components (A), (B) and (C):
[0007] (A) 5% to 25% by mass of one or more sugar alcohols selected from erythritol, xylitol, mannitol, maltitol, lactitol, and isomaltitol;
[0008] (B) Condensed phosphate or its salt; and
[0009] (C) Water;
[0010] Furthermore, the ratio of Helipath viscosity (x1) at 25°C to B8H viscosity (x2) at 25°C ((x1) / (x2)) is between 1 and 2.7.
[0011] Here, this oral composition containing sugar alcohols has a tendency to gradually dissolve during use and easily drip from the mouth. Therefore, it may pose a risk of inconvenience, especially for users who are prone to saliva production. There is still room for improvement.
[0012] That is, the present invention relates to an oral composition that can fully utilize the various excellent effects of sugar alcohols and prevent unnecessary dripping from the mouth during use.
[0013] Therefore, the inventors conducted focused research to solve the above-mentioned problems and discovered the following oral composition: by containing condensed phosphate or its salt, and water, and containing specific sugar alcohols such as erythritol in a specific amount, and having special viscosity characteristics, it can exert the excellent effects brought by sugar alcohols and effectively prevent dripping from the mouth during use.
[0014] The oral composition according to the present invention exhibits excellent spreadability when applied to the oral cavity and effectively prevents unnecessary dripping from the mouth. It improves adhesion not only to oral tissues such as teeth and gums but also to plaque, thereby effectively dispersing plaque and removing it efficiently. Therefore, it provides a comfortable brushing experience, allowing for extended brushing anywhere, and a truly pleasant brushing experience. Detailed Implementation
[0015] The present invention will now be described in detail.
[0016] It should be noted that, in this invention, "good spreadability" in the oral cavity means that when the oral composition of this invention is applied to the oral cavity, the oral composition quickly spreads to all corners of the oral cavity without excessive load. Furthermore, "good adhesion" in the oral cavity means that when the oral composition of this invention is applied to the oral cavity, unnecessary dripping from the oral cavity is effectively prevented, resulting in a tactile sensation as if the oral composition adheres to the oral cavity.
[0017] Furthermore, a "good user experience" means providing a pleasant cooling sensation and effectively preventing dripping from the mouth that could cause discomfort during use, allowing users to truly experience comfortable use.
[0018] The oral composition of the present invention contains 5% by mass and 25% by mass of one or more sugar alcohols selected from erythritol, xylitol, mannitol, maltitol, lactitol, and isomaltitol as component (A). As long as it is the oral composition of the present invention, the excellent plaque dispersibility provided by component (A) can be ensured, and unnecessary dripping from the oral cavity during use can be effectively prevented.
[0019] In terms of ensuring good adhesion in the oral cavity and exhibiting excellent plaque dispersibility, and providing a good user experience, component (A) is preferably selected from one or two of erythritol and xylitol, and more preferably erythritol.
[0020] Regarding the content of component (A), from the viewpoint of achieving both excellent plaque dispersibility and a pleasant user experience, in the oral composition of the present invention, it is 5% by mass or more, preferably 6% by mass or more, more preferably 7% by mass or more, and even more preferably 8% by mass or more, and 25% by mass or less, preferably 20% by mass or less, more preferably 15% by mass or less, and even more preferably 12% by mass or less. Furthermore, the content of component (A) in the oral composition of the present invention is 5% by mass or more and 25% by mass or less, preferably 6 to 20% by mass, more preferably 7 to 15% by mass, and even more preferably 8 to 12% by mass.
[0021] The oral composition of the present invention contains condensed phosphate or a salt thereof as component (B). This promotes the excellent plaque dispersibility provided by component (A) and ensures good adhesion within the oral cavity.
[0022] Specifically, examples of component (B) include linear polyphosphoric acids such as pyrophosphate, tripolyphosphate, and tetrapolyphosphate; cyclic polyphosphoric acids such as trimetaphosphate, hexametaphosphate, and tetramethacin; and salts thereof such as alkali metal salts or ammonium salts of sodium or potassium. From the viewpoint of promoting plaque dispersibility, component (B) is preferably selected from one or more of pyrophosphate, tripolyphosphate, hexametaphosphate, and their salts, and more preferably sodium pyrophosphate.
[0023] Regarding the content of component (B), from the viewpoint of achieving both excellent plaque dispersibility and a pleasant user experience, in the oral composition of the present invention, it is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, even more preferably 0.01% by mass or more, and preferably 0.5% by mass or less, even more preferably 0.4% by mass or less, and even more preferably 0.3% by mass or less. Furthermore, the content of component (B) in the oral composition of the present invention is preferably 0.001 to 0.5% by mass, more preferably 0.005 to 0.4% by mass, and even more preferably 0.01 to 0.3% by mass.
[0024] From the viewpoint of exhibiting excellent plaque dispersibility and good adhesion to effectively prevent unnecessary dripping, the mass ratio ((A) / (B)) of the content of component (A) to the content of component (B) is preferably 5 or more, more preferably 15 or more, and even more preferably 50 or more, and preferably 7000 or less, more preferably 4000 or less, and even more preferably 1000 or less. Furthermore, the mass ratio ((A) / (B)) of the content of component (A) to the content of component (B) is preferably 5 to 7000, more preferably 15 to 4000, and even more preferably 50 to 1000.
[0025] The oral composition of the present invention contains water as component (C). This helps to ensure proper solubility of component (A) and has the following special viscosity characteristics, and also maintains good spreadability in the oral cavity.
[0026] Regarding the content of component (C), in the oral composition of the present invention, it is preferably 20% by mass or more, more preferably 30% by mass or more, even more preferably 35% by mass or more, even more preferably 38% by mass or more, and preferably 60% by mass or less, even more preferably 50% by mass or less, even more preferably 45% by mass or less, even more preferably 43% by mass or less. Furthermore, the content of component (C) in the oral composition of the present invention is preferably 20 to 60% by mass, more preferably 30 to 50% by mass, even more preferably 35 to 45% by mass, even more preferably 38 to 43% by mass.
[0027] It should be noted that the water in component (C) of this invention refers to all the water contained in the oral composition, including not only purified water incorporated into the oral composition, but also the water contained in each of the incorporated components. By containing this water, the aforementioned components can be well dissolved or dispersed, thus fully exerting the desired effect.
[0028] The moisture content can also be calculated based on the moisture content of the formulated ingredients and the moisture content of the formulated components, for example, using a Karl Fischer moisture analyzer. As a Karl Fischer moisture analyzer, for example, a micro-moisture measuring device (manufactured by Hiranuma Sangyo Co., Ltd.) can be used. With this device, 5 g of the oral composition can be taken, suspended in 25 g of anhydrous methanol, and 0.02 g of the suspension can be aliquoted to determine the moisture content.
[0029] From the viewpoint of ensuring appropriate solubility of component (A) and exhibiting excellent plaque dispersibility, the mass ratio of the content of component (A) to the content of component (C) ((A) / (C)) is preferably 0.05 or more, more preferably 0.12 or more, and even more preferably 0.2 or more, and preferably 0.55 or less, more preferably 0.5 or less, and even more preferably 0.45 or less. Furthermore, the mass ratio of the content of component (A) to the content of component (C) ((A) / (C)) is preferably 0.05 to 0.55, more preferably 0.12 to 0.5, and even more preferably 0.2 to 0.45.
[0030] From the viewpoint of achieving both excellent plaque dispersibility and a pleasant user experience, the mass ratio of component (B) to component (C) ((B) / (C)) is preferably 0.00001 or more, more preferably 0.0001 or more, even more preferably 0.0002 or more, and preferably 0.05 or less, even more preferably 0.03 or less, and even more preferably 0.008 or less. Furthermore, the mass ratio of component (B) to component (C) ((B) / (C)) is preferably 0.00001 to 0.05, more preferably 0.0001 to 0.03, and even more preferably 0.0002 to 0.008.
[0031] Regarding the oral composition of the present invention, the ratio of the Helipath viscosity (x1) at 25°C to the B8H viscosity (x2) at 25°C ((x1) / (x2)) is 1 or more and 2.7 or less. By having this particular viscosity, the oral composition of the present invention exhibits good spreadability when applied to the oral cavity and effectively prevents unnecessary dripping, thereby improving adhesion within the oral cavity and effectively utilizing the excellent plaque dispersibility provided by component (A).
[0032] From the viewpoint of exhibiting good spreadability and effectively preventing unnecessary dripping, thus exhibiting excellent adhesion, the ratio of Helipath viscosity (x1) at 25°C to B8H viscosity (x2) at 25°C ((x1) / (x2)) is 1 or more, preferably 1.05 or more, more preferably 1.1 or more, even more preferably 1.15 or more, even more preferably 1.18 or more, even more preferably 1.21 or more, and is 2.7 or less, preferably 2.2 or less, even more preferably 1.9 or less, even more preferably 1.6 or less, even more preferably 1.3 or less.
[0033] Furthermore, regarding the oral composition of the present invention, the ratio of the Helipath viscosity (x1) at 25°C to the B8H viscosity (x2) at 25°C ((x1) / (x2)) is 1 or more and 2.7 or less, preferably 1.05 to 2.2, more preferably 1.1 to 1.9, even more preferably 1.15 to 1.6, even more preferably 1.18 to 1.3, and even more preferably 1.21 to 1.3.
[0034] From the viewpoint of ensuring a particular viscosity, the Helipath viscosity (x1) of the oral composition of the present invention at 25°C is preferably 1500 dPa•s or more, more preferably 2500 dPa•s or more, even more preferably 3500 dPa•s or more, even more preferably 4200 dPa•s or more, even more preferably 4500 dPa•s or more, and preferably 10000 dPa•s or less, even more preferably 9000 dPa•s or less, even more preferably 8000 dPa•s or less, even more preferably 7000 dPa•s or less, even more preferably 5800 dPa•s or more. Furthermore, the Helipath viscosity (x1) of the oral composition of the present invention at 25°C is preferably 1500 to 10000 dPa•s, more preferably 2500 to 9000 dPa•s, even more preferably 3500 to 8000 dPa•s, even more preferably 4200 to 7000 dPa•s, and even more preferably 4500 to 5800 dPa•s.
[0035] From the viewpoint of ensuring a particular viscosity, the B8H viscosity (x2) of the oral composition of the present invention at 25°C is preferably 1000 dPa•s or more, more preferably 2000 dPa•s or more, even more preferably 3200 dPa•s or more, even more preferably 3500 dPa•s or more, even more preferably 4100 dPa•s or more, and preferably 8000 dPa•s or less, even more preferably 7000 dPa•s or less, even more preferably 6000 dPa•s or less, even more preferably 5500 dPa•s or less, even more preferably 5000 dPa•s or less. Furthermore, the B8H viscosity (x2) of the oral composition of the present invention at 25°C is preferably 1000 to 8000 dPa•s, more preferably 2000 to 7000 dPa•s, even more preferably 3200 to 6000 dPa•s, even more preferably 3500 to 5500 dPa•s, and even more preferably 4100 to 5000 dPa•s.
[0036] From the viewpoint of ensuring a particular viscosity, the oral composition of the present invention preferably contains one or more binders (D) selected from sodium carboxymethyl cellulose, xanthan gum, carrageenan, hydroxyethyl cellulose, and sodium alginate. Of this component (D), one or two are preferably selected from sodium carboxymethyl cellulose and xanthan gum, and more preferably sodium carboxymethyl cellulose.
[0037] Regarding the total content of component (D), in the oral composition of the present invention, it is preferably 0.1% by mass or more, more preferably 0.4% by mass or more, even more preferably 0.8% by mass or more, even more preferably 1.2% by mass or more, and preferably 3% by mass or less, even more preferably 2.5% by mass or less, even more preferably 2% by mass or less, even more preferably 1.4% by mass or less. Furthermore, the total content of component (D) in the oral composition of the present invention is preferably 0.1 to 3% by mass, more preferably 0.4 to 2.5% by mass, even more preferably 0.8 to 2% by mass, even more preferably 1.2 to 1.4% by mass.
[0038] The oral composition of the present invention may further contain silica (E). Specifically, this component (E) may include one or more selected from abrasive silica with an oil absorption of 50 to 150 mL / 100 g, thickening silica with an oil absorption of 200 to 400 mL / 100 g, and silica with an oil absorption of more than 150 mL / 100 g and less than 200 mL / 100 g.
[0039] It should be noted that the oil absorption capacity refers to the amount of oil that silica can hold, which is a value specified by the amount of cooked linseed oil absorbed, determined by the method specified in JIS K5101-13-2 (established in 2004).
[0040] Regarding the total content of component (E), in the oral composition of the present invention, it is preferably 5% by mass or more, more preferably 15% by mass or more, and even more preferably 22% by mass or more, and preferably 35% by mass or less, more preferably 31% by mass or less, and even more preferably 27% by mass or less. Furthermore, the total content of component (E) in the oral composition of the present invention is preferably 5 to 35% by mass, more preferably 15 to 31% by mass, and even more preferably 22 to 27% by mass.
[0041] From the viewpoint of ensuring a particular viscosity, the average particle size of component (E) is preferably 3 μm or more, more preferably 4 μm or more, more preferably 5 μm or more, and preferably 20 μm or less, more preferably 15 μm or less, and more preferably 10 μm or less.
[0042] From the viewpoint of ensuring a specific viscosity and effectively preventing unnecessary dripping, the mass ratio of component (E) to component (D) ((E) / (D)) is preferably 1.6 or more, more preferably 8 or more, and even more preferably 15 or more, and preferably 300 or less, more preferably 100 or less, even more preferably 30 or less, and even more preferably 24 or less. Furthermore, the mass ratio of component (E) to component (D) ((E) / (D)) is preferably 1.6 to 300, more preferably 8 to 100, even more preferably 15 to 30, and even more preferably 15 to 24.
[0043] The oral composition of the present invention may further contain an acyl amino acid salt (F). By containing this component (F), the tartar removal effect resulting from the excellent tartar dispersibility of component (A) can be further enhanced.
[0044] As component (F), more specifically, the acyl group of the acyl amino acid salt is derived from saturated or unsaturated fatty acids having straight or branched chains, or a mixture of the latter, preferably from straight-chain fatty acids or a mixture of straight-chain fatty acids. The acyl group is preferably selected from one or more of lauroyl, myristoyl, palmitoyl, stearoyl, and cocoyl, more preferably from one or more of lauroyl, myristoyl, and stearoyl, and even more preferably from myristoyl.
[0045] Furthermore, the amino acid moiety of the acyl amino acid salt constituting component (F) can be any of glutamic acid, aspartic acid, or glycine, and can be any of the D-form, L-form, or a mixture of the D-form and L-form, preferably the L-form. Specifically, the acyl amino acid is preferably selected from one or more of lauroyl glutamic acid, myristoyl glutamic acid, stearoyl glutamic acid, cocoyl glutamic acid, lauroyl aspartic acid, myristoyl aspartic acid, cocoyl aspartic acid, lauroyl glycine, myristoyl glycine, stearoyl glycine, and cocoyl glycine, more preferably selected from one or two of lauroyl glutamic acid, myristoyl glutamic acid, and stearoyl glutamic acid, and even more preferably myristoyl glutamic acid.
[0046] Regarding the content of component (F), in the oral composition of the present invention, it is preferably 0.001% by mass or more, more preferably 0.01% by mass or more, and even more preferably 0.05% by mass or more, and preferably 0.5% by mass or less, more preferably 0.3% by mass or less, and even more preferably 0.15% by mass or less. Furthermore, the content of component (F) in the oral composition of the present invention is preferably 0.001 to 0.5% by mass, more preferably 0.01 to 0.3% by mass, and even more preferably 0.05 to 0.15% by mass.
[0047] From the viewpoint of achieving both excellent plaque dispersibility and a pleasant user experience, the mass ratio of component (F) to component (A) ((F) / (A)) is preferably 0.001 or more, more preferably 0.003 or more, and even more preferably 0.006 or more, and preferably 0.05 or less, more preferably 0.03 or less, and even more preferably 0.015 or less. Furthermore, the mass ratio of component (B) to component (C) ((B) / (C)) is preferably 0.001 to 0.05, more preferably 0.003 to 0.03, and even more preferably 0.006 to 0.015.
[0048] Without impairing the effects of the present invention, the oral composition of the present invention may further contain one or more surfactants selected from anionic surfactants, nonionic surfactants, and amphoteric surfactants other than the above-mentioned component (F).
[0049] As an anionic surfactant other than component (F), specifically, examples include one or more selected from alkyl sulfate salts such as sodium alkyl sulfate, sodium N-methyl long-chain acyl taurate such as sodium N-lauryl methyl taurate, alkyl phosphates such as sodium alkyl phosphate, sulfonated monoglyceride salts of higher fatty acids, fatty acid ester salts of hydroxyethanesulfonic acid, and polyoxyethylene monoalkyl phosphates.
[0050] Among these anionic surfactants other than component (F), one or more are preferably selected from alkyl sulfate salts such as sodium alkyl sulfate and sodium N-methyl long-chain acyl taurate salts such as sodium N-lauryl methyl taurate, with alkyl sulfate salts such as sodium alkyl sulfate being more preferred.
[0051] Regarding the content of the anionic surfactant other than component (F), in the oral composition of the present invention, it is preferably 0.1% by mass or more, more preferably 0.4% by mass or more, and even more preferably 0.7% by mass or more, and preferably 2.5% by mass or less, more preferably 2% by mass or less, and even more preferably 1.5% by mass or less. Furthermore, the content of the anionic surfactant other than component (F) in the oral composition of the present invention is preferably 0.1 to 2.5% by mass, more preferably 0.4 to 2% by mass, and even more preferably 0.7 to 1.5% by mass.
[0052] As nonionic surfactants, examples include: polyoxyethylene derivatives such as polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl allyl ether, polyoxyethylene styrene ether, and polyoxyethylene lanolin; polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, monocetylated glycerol ether, polyoxyethylene stearyl ether, and polyoxyethylene oil-based ether; and sorbitan monolaurate, sorbitan monooleate, sorbitan sesquioleate, and sorbitan monostearate. One or more of the following: sorbitan fatty acid esters such as esters; polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, and polyoxyethylene sorbitan monooleate; polyoxyethylene sorbitol fatty acid esters such as tetraoleic polyoxyethylene sorbitol; polyethylene glycol fatty acid esters such as polyethylene glycol monolaurate and polyethylene glycol monooleate; alkyl glycerol ethers such as isostearyl glycerol ether; and glycerol fatty acid esters such as monosorcinol ester.
[0053] Among these nonionic surfactants, polyoxyethylene derivatives and sorbitan fatty acid esters are preferred.
[0054] Regarding the content of the nonionic surfactant in the oral composition of the present invention, it is preferably 0.1% by mass or more, more preferably 0.2% by mass or more, even more preferably 0.3% by mass or more, and preferably 1.5% by mass or less, even more preferably 1% by mass or less, and even more preferably 0.7% by mass or less. Furthermore, the content of the nonionic surfactant in the oral composition of the present invention is preferably 0.1 to 1.5% by mass, more preferably 0.2 to 1% by mass, and even more preferably 0.3 to 0.7% by mass.
[0055] As an amphoteric surfactant, specifically, one or more of the following can be selected: amide betaine type amphoteric surfactants, imidazoline type amphoteric surfactants, acetate betaine type amphoteric surfactants, alkyl sulfobetaine, and amino acid type amphoteric surfactants.
[0056] As an amide betaine-type amphoteric surfactant, examples include coconut oil fatty acid amide propyl betaine and coconut oil fatty acid amide betaine.
[0057] As imidazoline-type amphoteric surfactants, examples include: 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazoline betaine, N-alkyl-1-hydroxyethylimidazoline betaine sodium, N-lauroyl-N'-carboxymethyl-N'-hydroxyethyl ethylenediamine sodium, N-cocoyl-N-carboxymethyl-N-hydroxyethyl ethylenediamine sodium, etc.
[0058] As an amphoteric surfactant of the acetate-betaine type, examples include lauryl dimethylaminoacetic acid betaine and coconut oil fatty acid amamidopropyl dimethylaminoacetic acid betaine.
[0059] As alkyl sulfonate betaines, examples include lauryl sulfonate betaine and lauryl hydroxy sulfonate betaine.
[0060] As an amino acid-type amphoteric surfactant, examples include N-lauryl diaminoethyl glycine and N-myristyl diaminoethyl glycine.
[0061] Among these amphoteric surfactants, amide betaine-type amphoteric surfactants and coconut oil fatty acid amide propyl betaine are preferred.
[0062] Regarding the content of the amphoteric surfactant, from the viewpoint of creating a viscous foam that enhances adhesion to plaque or effectively prevents dripping from the mouth, in the oral composition of the present invention, it is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, and even more preferably 0.2% by mass or more, and preferably 2.5% by mass or less, more preferably 1.5% by mass or less, and even more preferably 1% by mass or less. Furthermore, the content of the amphoteric surfactant in the oral composition of the present invention is preferably 0.01 to 2.5% by mass, more preferably 0.1 to 1.5% by mass, and even more preferably 0.2 to 1% by mass.
[0063] Without impairing the effects of the invention, the oral composition of the invention may further contain one or more polyols (G) selected from glycerol, ethylene glycol, propylene glycol, butylene glycol, and polyethylene glycol.
[0064] Regarding the content of component (G), from the viewpoint of exhibiting good spreadability, in the oral composition of the present invention, it is preferably 1% by mass or more, more preferably 3% by mass or more, and even more preferably 5% by mass or more, and preferably 45% by mass or less, more preferably 30% by mass or less, and even more preferably 15% by mass or less. Furthermore, the content of component (G) in the oral composition of the present invention is preferably 1 to 45% by mass, more preferably 3 to 30% by mass, and even more preferably 5 to 15% by mass.
[0065] From the viewpoint of enabling component (F) or surfactants other than component (F) and binder of component (D) to function effectively, exhibiting good spreadability, and effectively preventing unnecessary dripping from the oral cavity, the oral composition of the present invention preferably has a pH value of 6 or higher at 25°C, more preferably 6.5 or higher, even more preferably 7 or higher, and preferably 8.5 or lower, even more preferably 8 or lower, even more preferably 7.5 or lower. Furthermore, the oral composition of the present invention preferably has a pH value of 6 to 8.5 at 25°C, more preferably 6.5 to 8, even more preferably 7 to 7.5.
[0066] It should be noted that the pH value of the oral composition of the present invention is a value measured using a pH electrode at 25°C.
[0067] The oral composition of the present invention may further contain, as components other than those described above, fluoride, tocopheryl acetate, glycyrrhetinic acid and other pharmacologically active ingredients, antibacterial agents such as cetylpyridinium chloride, fragrance, sweetener, colorant and so on, without impairing the effects of the present invention.
[0068] Regarding the above embodiments, the present invention further discloses the following oral composition.
[0069] [1] An oral composition comprising the following components (A), (B) and (C):
[0070] (A) 5% to 25% by mass of one or more sugar alcohols selected from erythritol, xylitol, mannitol, maltitol, lactitol, and isomaltitol;
[0071] (B) Condensed phosphate or its salt; and
[0072] (C) Water;
[0073] Furthermore, the ratio of Helipath viscosity (x1) at 25°C to B8H viscosity (x2) at 25°C ((x1) / (x2)) is between 1 and 2.7.
[0074] [2] In the oral composition of [1] above, the content of component (A) is preferably 6% by mass or more, more preferably 7% by mass or more, more preferably 8% by mass or more, and preferably 20% by mass or less, more preferably 15% by mass or less, and more preferably 12% by mass or less.
[0075] [3] The oral composition as described in [1] or [2] above, wherein component (B) is preferably selected from one or more of pyrophosphate, tripolyphosphate, hexametaphosphate, and their salts, more preferably sodium pyrophosphate.
[0076] [4] The oral composition of any one of [1] to [3] above, wherein the content of component (B) is preferably 0.001% by mass or more, more preferably 0.005% by mass or more, more preferably 0.01% by mass or more, and preferably 0.5% by mass or less, more preferably 0.4% by mass or less, and more preferably 0.3% by mass or less.
[0077] [5] The oral composition of any one of [1] to [4] above, wherein the mass ratio of the content of component (A) to the content of component (B) ((A) / (B)) is preferably 5 or more, more preferably 15 or more, more preferably 50 or more, and preferably 7000 or less, more preferably 4000 or less, and more preferably 1000 or less.
[0078] [6] The oral composition of any one of [1] to [5] above, wherein the content of component (C) is preferably 20% by mass or more, more preferably 30% by mass or more, more preferably 35% by mass or more, more preferably 38% by mass or more, and preferably 60% by mass or less, more preferably 50% by mass or less, more preferably 45% by mass or less, and more preferably 43% by mass or less.
[0079] [7] The oral composition of any one of [1] to [6] above, wherein the mass ratio ((A) / (C)) of the content of component (A) to the content of component (C) is preferably 0.05 or more, more preferably 0.12 or more, and even more preferably 0.2 or more, and preferably 0.55 or less, more preferably 0.5 or less, and even more preferably 0.45 or less.
[0080] [8] The oral composition of any one of [1] to [7] above, wherein the mass ratio ((B) / (C)) of the content of component (B) to the content of component (C) is preferably 0.00001 or more, more preferably 0.0001 or more, and even more preferably 0.0002 or more, and preferably 0.05 or less, more preferably 0.03 or less, and even more preferably 0.008 or less.
[0081] [9] The oral composition of any one of [1] to [8] above, wherein the ratio of Helipath viscosity (x1) at 25°C to B8H viscosity (x2) at 25°C ((x1) / (x2)) is preferably 1.05 or more, more preferably 1.1 or more, even more preferably 1.15 or more, even more preferably 1.18 or more, even more preferably 1.21 or more, and preferably 2.2 or less, even more preferably 1.9 or less, even more preferably 1.6 or less, even more preferably 1.3 or less.
[0082]
[10] The oral composition of any one of [1] to [9] above, wherein the Helipath viscosity (x1) at 25°C is preferably 1500 dPa•s or more, more preferably 2500 dPa•s or more, more preferably 3500 dPa•s or more, more preferably 4200 dPa•s or more, more preferably 4500 dPa•s or more, and preferably 10000 dPa•s or less, more preferably 9000 dPa•s or less, more preferably 8000 dPa•s or less, more preferably 7000 dPa•s or less, and more preferably 5800 dPa•s or more.
[0083]
[11] The oral composition of any one of [1] to
[10] above, wherein the B8H viscosity (x2) at 25°C is preferably 1000 dPa•s or more, more preferably 2000 dPa•s or more, more preferably 3200 dPa•s or more, more preferably 3500 dPa•s or more, more preferably 4100 dPa•s or more, and preferably 8000 dPa•s or less, more preferably 7000 dPa•s or less, more preferably 6000 dPa•s or less, more preferably 5500 dPa•s or less, and more preferably 5000 dPa•s or less.
[0084]
[12] The oral composition of any one of [1] to
[11] above, wherein it further contains one or more binders (D) selected from sodium carboxymethyl cellulose, xanthan gum, carrageenan, hydroxyethyl cellulose and sodium alginate, wherein the content of the binder (D) is preferably 0.1% by mass or more, more preferably 0.4% by mass or more, more preferably 0.8% by mass or more, more preferably 1.2% by mass or more, and preferably 3% by mass or less, more preferably 2.5% by mass or less, more preferably 2% by mass or less, and more preferably 1.4% by mass or less.
[0085]
[13] The oral composition of any one of [1] to
[12] above, wherein, in turn, it contains silicon dioxide (E), the total content of which is preferably 5% by mass or more, more preferably 15% by mass or more, more preferably 22% by mass or more, and preferably 35% by mass or less, more preferably 31% by mass or less, and more preferably 27% by mass or less.
[0086]
[14] In the oral composition as described in
[12] or
[13] above, the mass ratio of the content of component (E) to the content of component (D) ((E) / (D)) is preferably 1.6 or more, more preferably 8 or more, more preferably 15 or more, and preferably 300 or less, more preferably 100 or less, more preferably 30 or less, and more preferably 24 or less.
[0087]
[15] The oral composition of any one of [1] to
[14] above, wherein the composition further comprises an acyl amino acid salt (F), wherein the content of the component (F) is preferably 0.001% by mass or more, more preferably 0.01% by mass or more, more preferably 0.05% by mass or more, and preferably 0.5% by mass or less, more preferably 0.3% by mass or less, and more preferably 0.15% by mass or less.
[0088]
[16] The oral composition of any one of [1] to
[15] above, wherein it further contains one or more polyols (G) selected from glycerin, ethylene glycol, propylene glycol, butylene glycol and polyethylene glycol, wherein the content of the component (G) is preferably 1% by mass or more, more preferably 3% by mass or more, more preferably 5% by mass or more, and preferably 45% by mass or less, more preferably 30% by mass or less, and more preferably 15% by mass or less.
[0089]
[17] In the oral composition as described in
[15] or
[16] above, the mass ratio of the content of component (F) to the content of component (A) ((F) / (A)) is preferably 0.001 or more, more preferably 0.003 or more, and even more preferably 0.006 or more, and preferably 0.05 or less, more preferably 0.03 or less, and even more preferably 0.015 or less.
[0090] [Example]
[0091] The present invention will now be specifically described based on embodiments. It should be noted that, unless otherwise specified, the content of each component in the table represents a percentage by mass.
[0092] It should be noted that each physical property is measured according to the following method.
[0093] Helipath Viscosity
[0094] Each of the obtained dental cleaning compositions was placed into a container for viscosity measurement and stored in a thermostat at 25°C for 24 hours. The viscosity was then measured using a Helipath viscometer (VISCOMETER TVB-10, manufactured by Toki Sangyo Co., Ltd.) at rotor TC, rotation speed 2.5 rpm, and for 1 minute.
[0095] B8H viscosity
[0096] Each of the obtained dental cleaning compositions was placed into a container for viscosity measurement and stored in a thermostat at 25°C for 24 hours. The viscosity was then measured using a B8H type viscometer (TVB-10R, manufactured by Toki Sangyo Co., Ltd.) at rotor H7, rotation speed 2.5 rpm, and for 1 minute.
[0097] [Examples 1-6, Comparative Examples 1-3]
[0098] Prepare the various oral compositions according to the formulations shown in Table 1.
[0099] Next, the obtained oral composition was used to perform various evaluations according to the following methods.
[0100] The results are shown in Table 1. It should be noted that the average particle size of component (E) in Examples 1-4 is 7.1 μm, the average particle size of component (E) in Examples 5-6 is 7.3 μm, and the pH value of the oral compositions in Examples 1-6 at 25°C is approximately 7.2.
[0101] Evaluation of plaque dispersibility
[0102] An in vitro dental plaque model (three bacterial species: Streptococcus mutans, Streptococcus gordonii, and Actinomyces viscosus) was established in a 24-well plate, and 1 ml of a 2-fold dilution of each of the prepared oral compositions was added. The plate was then stirred at 600 rpm for 3 minutes using a microplate shaker, followed by two cleaning cycles (cleaning: adding 1 ml of PBS and stirring at 400 rpm for 1 minute). The amount of plaque remaining was then determined using the phenol-sulfuric acid method.
[0103] Instead of adding any dental compositions, ion-exchanged water was used for treatment. Then, measurements were performed using the method described above. The measured amount of residual plaque was used as a baseline of 100%. After treatment with the aforementioned dental compositions, measurements were performed again. Based on the proportion of residual plaque, the plaque removal rate (%) was calculated. Plaque dispersibility was evaluated according to the following criteria. It should be noted that the better the plaque dispersibility, the higher the plaque removal rate.
[0104] AA: Tartar removal rate is over 65%.
[0105] A: The tartar removal rate is between 55% and 65%.
[0106] B: The tartar removal rate is above 40% but less than 55%.
[0107] C: The tartar removal rate is above 30% but less than 40%.
[0108] D: Tartar removal rate less than 30%
[0109] Evaluation of spreadability in the oral cavity
[0110] The "feeling of the oral composition spreading in the mouth (spreadability in the oral cavity)" when 1 g of each of the obtained oral compositions is placed in the oral cavity and brushing is started with a toothbrush is evaluated according to the following criteria.
[0111] AA: Spreads very well
[0112] A: Spread out well
[0113] B: Spread out slightly well
[0114] C: Slightly poor spreadability
[0115] D: Poor spreadability
[0116] Evaluation of Intraoral Adhesion
[0117] Place 1 g of each of the obtained oral compositions in the oral cavity and brush your teeth for 2 minutes. The "feeling of the oral composition adhering to the mouth (adhesion in the oral cavity)" from the start of brushing to the end is evaluated according to the following criteria.
[0118] AA: Provides a very good adhesive feel.
[0119] A: Achieve a good, adhesive-like tactile feel
[0120] B: Achieve a slightly good, adhesive-like feel.
[0121] C: The sticky, tactile feel is slightly unpleasant.
[0122] D: Unpleasant, sticky feel
[0123] [Table 1]
[0124]
[0125] Formulation examples 1 to 7 of the oral compositions of the present invention are shown in Table 2.
[0126] It should be noted that the values of the ratios (x1) / (x2) are all in the range of 1 to 2.7.
[0127] [Table 2]
[0128]
[0129] Formulation examples 8 to 12 of the oral compositions of the present invention are shown in Table 3.
[0130] [Table 3]
[0131]
Claims
1. An oral composition, wherein, It contains the following ingredients (A), (B) and (C): (A) 5% to 25% by mass of one or more sugar alcohols selected from erythritol, xylitol, mannitol, maltitol, lactitol, and isomaltitol; (B) Condensed phosphate or its salt; and (C) Water; Furthermore, the ratio of Helipath viscosity (x1) to B8H viscosity (x2) at 25°C (x1) / (x2) is between 1 and 2.
7.
2. The oral composition of claim 1, wherein, The mass ratio of the content of component (A) to the content of component (B) (A) / (B) is more than 5 and less than 7000.
3. The oral composition as described in claim 1 or 2, wherein, The mass ratio of the content of component (A) to the content of component (C) (A) / (C) is 0.05 or more and 0.55 or less.
4. The oral composition according to any one of claims 1 to 3, wherein, Furthermore, it contains one or more binders (D) selected from sodium carboxymethyl cellulose, xanthan gum, carrageenan, hydroxyethyl cellulose, and sodium alginate.
5. The oral composition according to any one of claims 1 to 4, wherein, It then contains silicon dioxide (E).
6. The oral composition of claim 5, wherein, The mass ratio of component (E) to component (D) is between 1.6 and 300.
7. The oral composition according to any one of claims 1 to 6, wherein, It further contains 0.001% by mass and less than 0.5% by mass of acyl amino acid salts (F).
Citation Information
Patent Citations
Composition for oral cavity
JP2014012655A
Oral composition
JP2018039742A
